Nanoparticle Packaging Dramatically Increases Potency of Anti-Cardiovascular Disease Drug
|
By LabMedica International staff writers Posted on 06 Jul 2015 |
![Image: The buildup of fatty substances in blood vessels caused by atherosclerosis stiffens and narrows the blood vessels resulting in the death of heart muscle (Photo courtesy of [US] National Heart, Lung, and Blood Institute). Image: The buildup of fatty substances in blood vessels caused by atherosclerosis stiffens and narrows the blood vessels resulting in the death of heart muscle (Photo courtesy of [US] National Heart, Lung, and Blood Institute).](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2015-07-06/GMS-208.jpg)
Image: The buildup of fatty substances in blood vessels caused by atherosclerosis stiffens and narrows the blood vessels resulting in the death of heart muscle (Photo courtesy of [US] National Heart, Lung, and Blood Institute).
The use of biodegradable polymer nanoparticles to encapsulate a promising drug for treating atherosclerosis increased its residence time in the body of a treated mouse from less than one hour to at least four hours (and up to 48 hours or longer).
The drug, D-PDMP (D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol), is a glycosphingolipid synthesis inhibitor. Previous studies had shown that it held considerable promise for the treatment of atherosclerosis and cardiac hypertrophy, but rapid in vivo clearance severely hindered its use in the clinical setting.
To overcome this impediment, investigators at Johns Hopkins University (Baltiomore, MD, USA) sequestered D-PDMP inside a biodegradable polymer composed of polyethylene glycol (PEG) and sebacic acid (SA).
Some PEG-SA nanoparticles were labeled with PEG that contained a radioactive iodine tracer to allow in vivo bio-distribution and release kinetics of D-PDMP to be determined by using gamma-scintigraphy and subsequently, by mass spectrometry. Results published in the June 3, 2015, online edition of the journal Biomaterials revealed that polymer encapsulation increased the residence time of D-PDMP in the body of a treated mouse from less than one hour to at least four hours (and up to 48 hours or longer).
The substantially increased in vivo longevity provided by polymer encapsulation resulted in a 10-fold gain in the drug's efficacy for interfering with atherosclerosis and cardiac hypertrophy in a model based on mice genetically engineered to lack the gene for the apolipoprotein E receptor that were fed a high fat and high cholesterol diet.
"Our experiments illustrate clearly that while content is important, packaging can make or break a drug," said senior author Dr. Subroto Chatterjee, professor of medicine and pediatrics at Johns Hopkins University. "In our study, the right packaging vastly improved the drug's performance and its ability not merely to prevent disease but to mitigate some of its worst manifestations."
Related Links:
Johns Hopkins University
The drug, D-PDMP (D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol), is a glycosphingolipid synthesis inhibitor. Previous studies had shown that it held considerable promise for the treatment of atherosclerosis and cardiac hypertrophy, but rapid in vivo clearance severely hindered its use in the clinical setting.
To overcome this impediment, investigators at Johns Hopkins University (Baltiomore, MD, USA) sequestered D-PDMP inside a biodegradable polymer composed of polyethylene glycol (PEG) and sebacic acid (SA).
Some PEG-SA nanoparticles were labeled with PEG that contained a radioactive iodine tracer to allow in vivo bio-distribution and release kinetics of D-PDMP to be determined by using gamma-scintigraphy and subsequently, by mass spectrometry. Results published in the June 3, 2015, online edition of the journal Biomaterials revealed that polymer encapsulation increased the residence time of D-PDMP in the body of a treated mouse from less than one hour to at least four hours (and up to 48 hours or longer).
The substantially increased in vivo longevity provided by polymer encapsulation resulted in a 10-fold gain in the drug's efficacy for interfering with atherosclerosis and cardiac hypertrophy in a model based on mice genetically engineered to lack the gene for the apolipoprotein E receptor that were fed a high fat and high cholesterol diet.
"Our experiments illustrate clearly that while content is important, packaging can make or break a drug," said senior author Dr. Subroto Chatterjee, professor of medicine and pediatrics at Johns Hopkins University. "In our study, the right packaging vastly improved the drug's performance and its ability not merely to prevent disease but to mitigate some of its worst manifestations."
Related Links:
Johns Hopkins University
Latest BioResearch News
- New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
- New Immune Target Could Support More Precise High Blood Pressure Treatment
- New Gene-Disease Link May Help Diagnose Rare Neurodevelopmental Disorders
- Researchers Identify Shared Molecular Networks Behind Fatigue-Related Illnesses
- Blood Metabolite Signature Predicts ALS Progression and Points to Treatment Strategy
- Whole-Blood Extracellular Vesicle Analysis Captures Molecular Signals Missed by Plasma Testing
- Age-Related Genomic Differences Could Refine Treatment Decisions in Lung Cancer
- Computational Tool Identifies Central Asthma Genes for Target Discovery
- Molecular Pathway Reveals Driver of Triple-Negative Breast Cancer Spread
- D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
- New Genetic Cause Identified for Neurodevelopmental Disorder
- New Genetic Discovery Could Support Precision Diabetes Care
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
Channels
Clinical Chemistry
view channel
Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection
Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more
Machine Learning Supports Targeted Screening for Elevated Lipoprotein(a)
Lipoprotein(a) is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease, yet routine screening remains uncommon despite guideline recommendations, leaving many high-risk... Read more
Blood Biomarker May Help Monitor Early Response to Lecanemab in Alzheimer’s Disease
Alzheimer’s disease is a progressive neurodegenerative disorder marked by amyloid-beta and tau pathology and remains a leading cause of cognitive decline in older adults. Although lecanemab, an anti-amyloid... Read moreMolecular Diagnostics
view channel
Blood-Based DNA Analysis Method Detects Early-Stage Solid Cancers
Early detection of stage I solid cancers remains a significant unmet clinical need. Liquid biopsy approaches that can distinguish tumor-derived signals from background cell-free DNA are therefore drawing... Read more
Combined Blood and Genetic Tests Estimate Timing of Alzheimer’s Symptom Onset
Predicting when Alzheimer’s disease will manifest remains a major clinical challenge, particularly before cognitive decline is evident. Blood biomarkers and genetic risk markers can flag elevated risk,... Read moreHematology
view channel
Hidden Molecular Mechanism Behind HIT Blood-Clotting Disorder Revealed
Immune-mediated thrombosis following heparin therapy can be sudden and severe, creating urgent diagnostic challenges. In heparin-induced thrombocytopenia (HIT), antibodies against platelet factor 4 (PF4)... Read more
Borderline Anemia May Carry Higher Risk Than Current Thresholds Suggest
Hemoglobin concentration is among the most frequently ordered blood tests in primary and hospital care. In older adults, both high and low values have been linked to adverse outcomes, including cognitive... Read moreImmunology
view channel
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read moreMicrobiology
view channelMagnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing
Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more
Infant Skin Microbiome Show Links to Later Eczema and Food Allergies
Eczema, or atopic dermatitis, and food allergies often begin in infancy and are among the earliest stages of the atopic march. Atopic dermatitis alone can affect up to 20% of children, yet objective indicators... Read more
Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
Hospitals face persistent pressure to improve diagnostic accuracy while reducing unnecessary testing and costs. Misordered or overused assays can complicate infection metrics, trigger penalties, and strain... Read more
Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read morePathology
view channel
AI Spatial Analysis of Routine Slides Helps Predict Pancreatic Cancer Recurrence
Predicting which patients with pancreatic cancer will recur after treatment and surgery remains challenging. Pathology evaluation typically measures residual tumor burden, but recent work found that tumor... Read more
Hybrid Computational Imaging Method Improves Digital Pathology Resolution
Digital pathology depends on high-resolution whole-slide imaging to capture diagnostically relevant cellular and tissue features, yet conventional methods often force trade-offs between speed, cost, and detail.... Read moreTechnology
view channel
Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read moreIndustry
view channel
Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities
Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Unilabs Expands Digital Pathology Across European Network with Proscia Platform
As precision medicine expands, digital pathology platforms must connect teams, sites, diagnostic data, and artificial intelligence to accelerate routine diagnosis. Sharing expertise across laboratory networks... Read more
MGI Launches Automated Multiplex Tissue Staining and Imaging System at ECP 2026
MGI Tech Co., Ltd. (Shenzhen, China) introduced VisiOmics (PMIF-20RS), a fully automated multiplex immunofluorescence staining and imaging system, at the 38th European Congress of Pathology (ECP 2026)... Read more







